According to Xianju Pharmaceutical's announcement, the company holds 32.1957% of the shares in the participating company Zhejiang Cuize Pharmaceutical Technology Co., Ltd., and Cuize Pharmaceutical plans to add a registered capital of 4202.64 million yuan, which will be subscribed by Zhejiang Xianan Pharmaceutical Investment Partnership with 20 million yuan in cash. Based on its development strategy and R&D positioning, the company decided to relinquish the right to give up priority funding for this capital increase. After completion, the shareholding ratio will drop to 31.4512%, which will not have a significant impact on the company's finance and operations.

Zhitongcaijing · 1d ago
Xianju Pharmaceutical announced that the company holds 32.1957% of the shares in the participating company Zhejiang Cuize Pharmaceutical Technology Co., Ltd., and Cuize Pharmaceutical plans to add 4202.64 million yuan in registered capital, which will be subscribed by Zhejiang Xianan Pharmaceutical Investment Partnership with 20 million yuan in cash. Based on its development strategy and R&D positioning, the company decided to relinquish the right to give up priority funding for this capital increase. After completion, the shareholding ratio will drop to 31.4512%, which will not have a significant impact on the company's finance and operations.